Unimed's nitazoxanide for Cryptosporidium parvum in AIDS patients starts Phase II.
Executive Summary
UNIMED NITAZOXANIDE FOR CRYPTOSPORIDIUM PARVUM IN AIDS PATIENTS begins Phase II trial that will include 298 patients, Buffalo Grove, Ill.-based Unimed Pharmaceuticals announced Sept. 19. Unimed, which co-markets its Marinol (dronabinol) for AIDS wasting with Roxane Labs, said the NTZ trial will be conducted at Cornell Medical Center, New York City. The principal investigator, Rosemary Soave, MD, is an "internationally known" Cryptosporidium expert, Unimed said.